Paclitaxel-Carboplatin Alone or With M2ES for Non-Small-Cell Lung Cancer
Conditions
Non Small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms
Conditions: Keywords
NSCLC
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Intervention
Name: pegylated endostatin and Paclitaxel-Carboplatin Type: Drug
Name: Placebo and Paclitaxel-Carboplatin Type: Drug
Overall Status
Recruiting
Summary
A phase II, multicenter, randomized, double-blind, placebo-controlled study was carried out. Patients were randomly assigned to the treatment (PC + pegylated endostatin) or the control group (PC+ placebo). The efficacy was evaluated every six weeks.Follow-up continued until disease progression or death.
Detailed Description
A randomized phase 2 study, involving patients with advanced non-small-cell lung cancer who had not previously received chemotherapy, compared paclitaxel and carboplatin Plus placebo with paclitaxel and carboplatin plus PEGylated endostatin, with PEGylated endostatin at a dose of 10 mg/m2 intravenously every weeks.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed, newly diagnosed stage IIIB or stage IV cancer or recurrent non-small-cell lung cancer for which they had not received chemotherapy, targeted therapy.

2. Prior radiation therapy was allowed provided that the only sites disease were not located in lung.

3. Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).

4. ≥18 years of age.

5. ECOG performance status of 0 or 1.

6. Life expectancy of at least 12 weeks.

7. Adequate hematologic, hepatic, and renal function.

8. Patients are voluntary to participate and sigh the informed contents.

Exclusion Criteria:

1. Major surgery within the prior 4 weeks.

2. Participating any clinical trial within the prior 4 weeks.

3. Patients had clinically apparent CNS disease ( primary brain tumors, tumor related apoplexy, CNS metastases, carcinomatous meningitis.)

4. Another active malignancy, or any history of other malignancy within the past 3 years except for nonmelanoma skin cancer and carcinoma in situ of the cervix.

5. Pregnant or lactating women.

6. Radiation therapy have not been completed 4 weeks before enrollment.

7. Pulmonary embolus, deep venous thrombosis or bleeding diathesis.

8. Uncontrolled intercurrent illness as following: prior or ongoing uncontrolled hypertension;angina pectoris; congestive cardiac failure; myocardial ischemia, infarction, uncompensated coronary artery disease within the past 12 months; Uncontrolled arrhythmia; Uncontrolled diabetes mellitus; Uncontrolled infection.

9. Grade 2 hemoptysis within the past 6 months.

10. Acute or chronic renal disease.

11. Active hepatitis or HIV.

12. ECG: QTC ≥ 480 ms.

13. Patients on therapeutic doses of heparin.

14. Other conditions that are regarded for exclusion by the investigator.
Location
Cancer hospital, Chinese academy of medical science
Beijing, Beijing, China
Status: Recruiting
Contact: Yan Sun, MD - 8610-87788495 - cancergcp@163.com
Start Date
May 2011
Completion Date
April 2013
Sponsors
Protgen Ltd
Source
Protgen Ltd
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page